Loading
West Pharmaceutical Services Inc Stock: price and insider trades · United States
West Pharmaceutical Services Inc: what insiders have been doing
This page follows insider dealings at West Pharmaceutical Services Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Exton, United States. The group dates from 1923. 7 insiders have disclosed 30 filings since 21 October 2025.
Only sales appear on the open market, 8 sales in all totalling €5.7M, filed by 2 insiders. The largest single trade was a sale of €826k by Favorite Annette F, published on 10 September 2026, equal to 0.0036% of the market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 30 filings here. Looking back to 2016, when coverage begins, insiders filed no purchases and 19 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 3.07 bn USD and net income of 493.7 m USD, with a dividend of 0.86 USD per share.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
172
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€25M
19 ops. · all time
Who traded when
BuySaleAnnette F. Favorite7 sales
Chad Winters1 sale
Analyst consensus: bullish or bearish?
Analysts rate West Pharmaceutical Services Inc Strong Buy (bullish), based on 16 analysts. Average price target: US$412.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,690 of 26,279 companies
54.4
score / 100
Value33
Quality76
FCF yld1.7%
Earn yld1.8%
EV/EBITDA35.8x
ROE19%
Gross mgn36%
Net mgn16%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$383.02
Analyst consensus
16 analystsStrong buy
US$340.00Target US$412.88(+8%)US$459.00
Income statement
RevenueUS$3.1B
Gross profitUS$1.1B36% margin
EBITDAUS$772.8M25% margin
Net incomeUS$493.7M17.0% margin
Valuation
PER (trailing)49.0x
PER (forward)38.3x
P/Book9.0x
Beta1.13
Balance sheet & cash
Market capUS$27B
Total debtUS$321.1M
Free Cash FlowUS$468.9M
Debt / Equity11%
Profitability & ownership
ROE19.1%
ROA11.4%
% insiders0.7%
% institutions101.9%
Last declaration on 15 September 2026
Declarations172 total
2,500 shares@ US$345.000.0032% mcap12.6% of flowCommon StockSEC:0000105770-26-000110:1
2,500 shares@ US$355.000.0033% mcap13.0% of flowCommon StockSEC:0000105770-26-000110:3
2,500 shares@ US$89.640.0008% mcap3.3% of flowCommon StockSEC:0000105770-26-000110:0
2,500 shares@ US$89.640.0008% mcap3.3% of flowCommon StockSEC:0000105770-26-000110:2
2,524 shares@ US$89.640.0008% mcap3.3% of flowCommon StockSEC:0000105770-26-000110:4
2,524 shares@ US$365.000.0035% mcap13.6% of flowCommon StockSEC:0000105770-26-000110:5
2,817 shares@ US$83.470.0009% mcap3.4% of flowCommon StockSEC:0000105770-26-000108:0
2,817 shares@ US$340.810.0036% mcap14.1% of flowCommon StockSEC:0000105770-26-000108:1
2,818 shares@ US$83.470.0009% mcap3.4% of flowCommon StockSEC:0000105770-26-000108:2
2,818 shares@ US$340.810.0036% mcap14.1% of flowCommon StockSEC:0000105770-26-000108:3
2,500 shares@ US$89.640.0008% mcap3.3% of flowCommon StockSEC:0000105770-26-000108:4
2,500 shares@ US$340.810.0032% mcap12.5% of flowCommon StockSEC:0000105770-26-000108:5
345.515 shares@ US$351.370.0005% mcap11.1% of flowCommon StockSEC:0000105770-26-000104:1
2,763.675 shares@ US$351.370.0036% mcap88.9% of flowCommon StockSEC:0000105770-26-000104:3
794.469 sharesCommon StockSEC:0000105770-26-000104:0
6,354.736 sharesCommon StockSEC:0000105770-26-000104:2
295.995 sharesCommon StockSEC:0000105770-26-000075:0
2,817 shares@ US$83.470.0009% mcap6.4% of flowCommon StockSEC:0000105770-26-000054:0
2,817 shares@ US$305.20180.0032% mcap23.2% of flowCommon StockSEC:0000105770-26-000054:1
896 shares@ US$173.220.0006% mcap12.8% of flowCommon StockSEC:0000105770-26-000053:0
896 shares@ US$300.66880.0010% mcap22.3% of flowCommon StockSEC:0000105770-26-000053:1
60.22 sharesCommon StockSEC:0000105770-26-000024:0
89.328 sharesCommon StockSEC:0000105770-26-000023:0
383.382 sharesCommon StockSEC:0000105770-26-000025:0
115.91 shares0Common StockSEC:0000105770-26-000019:0
25 of 172 declarations
About West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. (NYSE: WST) is a leading player in the healthcare supply chain in the United States. Headquartered in Exton, Pennsylvania, the company develops and supplies high-value solutions for the containment, packaging, and delivery of injectable medicines. Its customer base consists primarily of pharmaceutical companies, biotechnology firms, and drug developers, with a particularly strong position in sterile injectable and complex therapy applications. Founded in 1923, West has built its reputation over decades as a critical partner to the injectable drug industry, supported by expertise in materials science, precision engineering, and regulatory compliance. ([investor.westpharma.com](https://investor.westpharma.com/?utm_source=openai))
West operates through two main segments. The first, Proprietary Products, includes the company’s own branded components and systems for injectable drugs: high-value components, closure solutions, delivery devices, and standard products. The second, Contract-Manufactured Products, covers contract manufacturing activities, including work related to self-injection devices and other injectable delivery systems. This structure gives West a hybrid profile: it is both a manufacturer of essential components and a development/industrial partner for pharmaceutical customers. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai))
Read moreShow less
From a competitive standpoint, West occupies a niche but strategically important position. The company does not sell a drug itself; instead, it provides critical inputs that protect product integrity, support accurate dosing, and enable safe administration. That makes it deeply embedded in the pharma value chain and often difficult to replace, especially for high-specification injectable products. Recent product focus has included Westar®, Envision®, NovaPure®, Daikyo PLASCAP®, and SmartDose®, showing the breadth of its technology platform and its emphasis on higher-value offerings. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai))
Geographically, West has a global footprint, with operations centered in the United States and manufacturing/commercial capabilities across multiple regions. Recent disclosures highlighted the expansion of its Dublin facility to support high-volume injectable therapies, including diabetes and obesity, reinforcing exposure to large, secular growth markets in modern healthcare. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-expands-dublin-facility-support-high-volume-injectable?utm_source=openai))
Recent developments have been constructive. In 2025, West delivered solid results and raised guidance, and in the first quarter of 2026 it reported strong revenue and earnings growth while lifting full-year expectations again. The company also announced a planned divestiture of SmartDose® 3.5mL to AbbVie, alongside continued industrial investment and share repurchases. For French-speaking investors, West therefore stands out as a high-quality Healthcare & Pharma name listed on the U.S. NYSE market in the United States, with attractive exposure to injectable delivery systems, biologics, and long-term pharmaceutical outsourcing trends. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
